Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

September 14, 2020

Primary Completion Date

February 26, 2021

Study Completion Date

March 22, 2021

Conditions
COVID-19
Interventions
DRUG

Remdesivir (RDV)

Administered as an aerosolized solution

DRUG

Placebo

Administered as an aerosolized solution

Trial Locations (28)

33013

Research in Miami, Inc., Hialeah

33016

Evolution Clinical Trials, Inc., Hialeah Gardens

33125

Optimus U Corporation, Miami

33144

L & C Professional Medical Research Institute, Miami

33155

Westchester Research Center at Westchester General Hospital, Miami

33157

IMIC Inc, Palmetto Bay

33166

Integrity Clinical Research, LLC, Doral

33180

MedBio Trials, Miami

33186

Nuovida Research Center, Corp, Miami

33308

Holy Cross Hospital, Fort Lauderdale

33401

Triple O Research Institute, PA, West Palm Beach

34205

Bradenton Research Center, Inc., Bradenton

45066

STAT Research, Vandalia

70112

CTU Covid Research Center, New Orleans

75234

DFW Clinical Research, Dallas

75246

Baylor Research Institute, Dallas

77093

PCP for Life-Tidwell, Houston

77521

Inquest Clinical Research, Baytown

83704

Family Care Research, Boise

85210

The Institute for Liver Health, Mesa

85712

The Institute for Liver Health, Tucson

90048

Cedars-Sinai Medical Center, Los Angeles

92627

Aurora FDRC Inc., Costa Mesa

92648

Elevated Health, Huntington Beach

92870

Western Clinical Research, Placentia

93301

Franco Felizarta, MD, Bakersfield

95817

UC Davis Health/Medical Center, Sacramento

98201

Providence Regional Medical Center Everett, Everett

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY